ArgenX rises after European Commission approves immune disorder drug

argenx SE

20/06/2025 18:31

** U.S.-listed shares of Belgian biotech firm ArgenX ARGX.BR, ARGX.O rise 1.2% to $544.14

** ARGX says that the European Commission approved its subcutaneous injection of blockbuster immune disorder drug, Vyvgart

** The drug is approved to treat patients with a type of autoimmune disorder called chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), in which the body's immune system attacks the myelin that insulates and protects the body's nerves

** The EC approval follows a positive recommendation from the Committee for Medicinal Products for Human Use — ARGX

** Vyvgart was already approved in Europe as an add-on to standard therapy to treat adult patients with a rare autoimmune disease called generalized myasthenia gravis (gMG)

** Including sessions' moves, stock down 21.5% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))